Health
Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial – News-Medical.Net
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled…
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.
Dupilumab also rapidly improved lung function…
-
General13 hours agoGwalia resident works to save century-old home in ‘living ghost town’
-
Business13 hours ago2 ASX 200 large-cap shares that this fundie is cashing in after phenomenal growth
-
Noosa News13 hours agoAustralia’s biggest sheep drive, and the young drover history forgot
-
Noosa News15 hours agoNow Open: The Family Behind Merlo Coffee Continues Its Legacy in Bowen Hills with the Arrival of Milano Bakehouse